Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of $0.16, $0.02 better than the analyst estimate of $0.14. Revenue for the quarter came in at $70 million versus the consensus estimate of $64.27 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2025 revenue of $260-270 million, versus the consensus of $258.2 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.